These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38804583)

  • 1. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [
    Xiao L; Xiang S; Chen C; Zhu H; Zhou M; Tang Y; Feng L; Hu S
    Psychiatry Clin Neurosci; 2024 Aug; 78(8):456-467. PubMed ID: 38804583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring with [
    Serrano ME; Bahri MA; Becker G; Seret A; Germonpré C; Lemaire C; Giacomelli F; Mievis F; Luxen A; Salmon E; Rogister B; Raedt R; Plenevaux A
    Mol Imaging Biol; 2020 Oct; 22(5):1197-1207. PubMed ID: 32206990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An
    Li J; Huang Q; Qi N; He K; Li S; Huang L; Pan F; Ren S; Hua F; Huang Y; Guan Y; Guo Q; Zhao J; Xie F
    J Cereb Blood Flow Metab; 2024 Jul; 44(7):1199-1207. PubMed ID: 38295871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subchronic cerebrolysin treatment alleviates cognitive impairments and dendritic arborization alterations of granular neurons in the hippocampal dentate gyrus of rats with temporal lobe epilepsy.
    Zamudio SR; Pichardo-Macías LA; Díaz-Villegas V; Flores-Navarrete IL; Guzmán-Velázquez S
    Epilepsy Behav; 2019 Aug; 97():96-104. PubMed ID: 31207446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment with levetiracetam reverses deficits in hippocampal LTP in vivo in experimental temporal lobe epilepsy rats.
    Ge YX; Tian XZ; Lin YY; Liu XY
    Neurosci Lett; 2016 Aug; 628():194-200. PubMed ID: 27345386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatio-Temporal Alterations in Synaptic Density During Epileptogenesis in the Rat Brain.
    Mikkelsen JD; Aripaka SS; Bascuñana P; Bankstahl M; Bankstahl JP; Pazarlar BA
    Neuroscience; 2022 Sep; 499():142-151. PubMed ID: 35878719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of Synaptic Density in Neurodegenerative Disorders.
    Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ
    J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal hippocampal functional network and related memory impairment in pilocarpine-treated rats.
    Jiang Y; Han CL; Liu HG; Wang X; Zhang X; Meng FG; Zhang JG
    Epilepsia; 2018 Sep; 59(9):1785-1795. PubMed ID: 30073661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic density in aging mice measured by [
    Xiong M; Roshanbin S; Sehlin D; Hansen HD; Knudsen GM; Rokka J; Eriksson J; Syvänen S
    Neuroimage; 2023 Aug; 277():120230. PubMed ID: 37355199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.